ClinicalTrials.gg
CompletedNCT05921903RSV OA=ADJ-023Updated Jun 11, 2026Results posted

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

A Phase 2 interventional study of RSVPreF3 OA Investigational Vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 46 sites in 8 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
386
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.

Enrollment
15th of 17
386 · median 976
Started
2023
with 1 other
Phase 2
2 of 17
1 open now
Registered
8th of 17
by date
Lead sponsor
15 of 17
GlaxoSmithKline

Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 15th largest by enrollment, is one of 2 that started in 2023, is one of 2 in phase 2, and was the 8th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About arexvy

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing arexvy in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of the RSVPreF3 OA investigational vaccine in an immunocompromised (lung and renal transplant recipients) population and assess whether a second dose of the vaccine increases the immune response.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory syncytial virus
  • Vaccine
  • Immunogenicity
  • Safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants and/or participant's parent(s)/LAR(s) who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Participants living in the general community or in an assisted-living facility that provides minimal assistance can be enrolled, such that the participant is primarily responsible for self-care and activities of daily living.
  • Written or witnessed obtained from the participant/participant's parent(s)/LAR(s) (participant must be able to understand the informed consent) prior to performance of any study-specific procedure.
  • Female participants of nonchildbearing potential may be enrolled in the study. Non- is defined as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, and .
  • Female participants of childbearing potential may be enrolled in the study if the participant has practiced adequate from 1 month prior to study intervention administration and agreed to continue adequate contraception until study end for this study, and has a negative pregnancy test on the day of and prior to study intervention administration.

Specific inclusion criteria for renal/lung transplant patients:

  • A male or female, >=18 YoA at the time of signing the Informed consent form (ICF) or Informed assent form (IAF).
  • Written informed assent obtained from the participant (participant must be able to understand the informed assent) if he/she is less than legal age of consent, or written informed consent obtained from the participant if the participant has achieved legal age of consent.
  • Participant who has received an ABO compatible allogeneic renal or lung transplant (allograft) more than 12 months (365 days) prior to the first study intervention administration.
  • Participant receiving maintenance therapy for the prevention of allograft rejection.

Specific inclusion criteria for renal transplant (RTx) patients:

  • Participant with stable renal function, stability defined as less than 20% variability between last two results of or in the opinion of the investigator after investigator review of more than the last two results of eGFRs and based on medical history.

Specific inclusion criteria for lung transplant (LTx) patients:

  • Participant with stable lung function, with stability defined as the stability in the compared to post-transplant baseline FEV1 and based on medical history of the last 3 months, in the opinion of the investigator.

Specific inclusion criteria for healthy participants:

  • A male or female, >=50 YoA at the time of signing the ICF.
  • Healthy participants as established by medical history and clinical examination before entering the study.
  • Participants who are medically stable in the opinion of the investigator at the time of first study intervention administration.
  • Participants with chronic stable medical conditions with or without specific treatment, such as diabetes mellitus, hypertension, or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable.

Exclusion criteria

Exclusion Criteria:

Medical conditions:

  • History of any reaction/ likely to be exacerbated by any component of the study intervention.
  • Acute or chronic cardiovascular or hepatic functional abnormality as determined by physical examination or laboratory screening tests.
  • Recurrent/uncontrolled neurological disorders or seizures. Participants with medically controlled chronic neurological diseases can be enrolled in the study if their condition will allow them to comply with the requirements of the protocol, with the help of a caregiver if needed.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.
  • Any condition which would make IM injection unsafe.
  • Significant underlying illness that would prevent completion of the study).
  • Acute disease and/or fever at the time of study intervention administration (>=38°C /100.4°F, oral or axillary). Participants with a minor illness without fever may be enrolled at the discretion of the investigator.
  • Bedridden participants.

Prior/Concomitant therapy:

  • Use of any other or non-registered product (drug, vaccine, or medical device) up to 30 days before the first dose administration (Day -30 to Day 1), or their planned use during the study period (up to Visit 6).
  • Previous vaccination with the study antigen (RSV), including investigational RSV vaccines.
  • Unexpected vaccine administration during a study should not occur 30 days prior to the first dose or 30 days after the last dose. For COVID-19 and inactivated/subunit/split influenza vaccines, this window is shortened to 14 days.

Prior/Concurrent clinical study experience:

  • Concurrently participating in another active clinical study

Other exclusion criteria:

  • Pregnant or lactating female participant.
  • Female participant planning to become pregnant or planning to discontinue precautions.
  • History of chronic alcohol consumption and/or drug abuse
  • Participation of any study personnel or their immediate dependents.
  • Planned move during the study period that will prohibit participating in the study until study end.

Specific exclusion criteria for renal/lung transplant patients:

  • More than one organ transplanted. Dual organ is allowed.
  • History of events that may put the participant at increased risk for chronic allograft dysfunction.
  • Participant with an episode of allograft rejection over the previous 90 days prior to the first study intervention administration.
  • Histologic evidence of chronic allograft injury.
  • Active treatment for acute rejection.
  • Current diagnosis of (except non-melanoma skin cancer that does not require systemic therapy).
  • Any conditions or pIMDs that may put the participant at increased risk.
  • Any confirmed or suspected infection, primary immunodeficiency disease or ongoing CMV infection with a viremia >200 IU/mL.
  • Use of anti-CD20 or other B-cell monoclonal antibody agents for the prevention of allograft rejection within 274 days of first dose of study.
  • Use of investigational and non-registered at the local/country level, unless specifically prescribed for the prevention of allograft rejection, and which are in process of approval, approved in other countries and locally available.
  • Evidence/high suspicion\ of noncompliance/nonadherence to use of induction and/or maintenance immunosuppressive therapies.
  • Any clinically significant hematologic and/or biochemical laboratory abnormality.

Specific exclusion criteria for RTx patients:

  • Previous allograft loss secondary to recurrent primary kidney disease. Multiple consecutive kidney transplants are allowed if the reason is not recurrent primary kidney disease.
  • Evidence of significant proteinuria/albuminuria.

Specific exclusion criteria for LTx patients:

  • At study intervention administration visit, diagnosis of documented acute pulmonary infection within the 2 prior weeks.
  • Patients with diagnosis of chronic lung allograft dysfunction (decrement of >=20% in compared to post-transplant baseline FEV1).

Specific exclusion criteria for healthy participants:

  • Any confirmed/suspected immunosuppressive/immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination.
  • Unstable serious chronic illness.
  • Chronic administration of immune-modifying drugs (>14 days in total) and/or administration of long-acting immune-modifying treatments or planned administration at any time up to the end of the study.

    • Up to 3 months prior to the study intervention administration:
    • For -prednisone equivalent ≥20 mg/day, or equivalent. Inhaled, topical and intra-articular steroids are allowed.
    • Administration of immunoglobulins and/or any blood products or plasma derivatives.
    • Up to 6 months prior to study intervention administration: long-acting immune-modifying drugs.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
386 participants (actual)

Study arms

  • Experimental
    RSV_IC_1 group

    Immunocompromised (IC) participants (recipients of lung or renal transplant) received 1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1).

    Biological: RSVPreF3 OA Investigational Vaccine

  • Experimental
    RSV_IC_2 group

    IC participants (recipients of lung or renal transplant) received 2 doses of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1) and Visit 3 (Visit 1 + 30-60 days).

    Biological: RSVPreF3 OA Investigational Vaccine

  • Active comparator
    RSV_HA group

    Healthy adult (HA) participants received 1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1).

    Biological: RSVPreF3 OA Investigational Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. RSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group

    MGI was defined as the geometric mean of the within-participant ratios of serum neutralizing titers against RSV-A post-Dose 2 (Visit 4) over post-Dose 1 (Visit 3).

    Time frame: At Visit 4 (Visit 3 + 30-42 days) compared with Visit 3 (Visit 1 [Day 1] + 30-60 days)

  2. RSV-B Serum Neutralizing Titers Expressed As MGI Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group

    MGI was defined as the geometric mean of the within-participant ratios of serum neutralizing titers against RSV-B post-Dose 2 (Visit 4) over post-Dose 1 (Visit 3).

    Time frame: At Visit 4 (Visit 3 + 30-42 days) compared with Visit 3 (Visit 1 [Day 1] + 30-60 days)

Secondary outcomes

  1. RSV-A And RSV-B Serum Neutralizing Titers Expressed As Geometric Mean Titers (GMT) for RSV_IC_1, RSV_IC_2 and RSV_HA Groups

    Neutralizing titers were calculated as GMT and expressed in titers (Estimated Dilution 60 \[ED60\]).

    Time frame: At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 in a subset of participants (Visit 1+ 7-14 days), Visit 3 (Visit 1+ 30-60 days), Visit 4 (Visit 3+ 30-42 days), Visit 5 (last dose+ 180-210 days) and Visit 6 (last dose+ 350-380 days)

  2. RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_HA And Pooled RSV_IC Groups

    Group GMT was assessed for RSV\_HA group over pooled RSV\_IC group (combined RSV\_IC\_1 and RSV\_IC\_2 groups). The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_HA and Pooled RSV\_IC groups in the model as fixed effect, as specified in Statistical Analysis Plan.

    Time frame: At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days) and Visit 3 (Visit 1 + 30-60 days)

  3. RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_IC_2 Groups

    Group GMT of RSV\_IC\_2 over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer and the SOT type as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_IC\_2 groups in the model as fixed effect, as specified in Statistical Analysis Plan.

    Time frame: At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)

  4. RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_HA Groups

    Group GMT of RSV\_HA over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.

    Time frame: At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)

  5. RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_2 And RSV_HA Groups

    Group GMT of RSV\_HA over RSV\_IC\_2 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_2 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.

    Time frame: At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)

  6. RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_HA And Pooled RSV_IC Groups

    Group GMT was assessed for RSV\_HA group over pooled RSV\_IC group (combined RSV\_IC\_1 and RSV\_IC\_2 groups). The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_HA and Pooled RSV\_IC groups in the model as fixed effect, as specified in Statistical Analysis Plan.

    Time frame: At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days) and Visit 3 (Visit 1 + 30-60 days)

  7. RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_IC_2 Groups

    Group GMT ratio of RSV\_IC\_2 over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer and the SOT type as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_IC\_2 groups in the model as fixed effect, as specified in Statistical Analysis Plan.

    Time frame: At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)

  8. RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_HA Groups

    Group GMT of RSV\_HA over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.

    Time frame: At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)

  9. RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_2 And RSV_HA Groups

    Group GMT of RSV\_HA over RSV\_IC\_2 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_2 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.

    Time frame: At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)

  10. RSV-A And RSV-B Serum Neutralizing Titers Expressed As MGI

    MGI was assessed at Visit 2 (in a subset of participants) over Visit 1 and Visit 3 over Visit 1 in RSV\_HA and pooled RSV\_IC (combined RSV\_IC\_1 and RSV\_IC\_2 groups), and at Visit 4, Visit 5 and Visit 6 over Visit 1 in RSV\_IC\_1, RSV\_IC\_2, RSV\_HA groups.

    Time frame: At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days), Visit 3 (Visit 1 + 30-60 days), Visit 4 (Visit 3 + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days), each compared to Visit 1 (Day 1)

  11. Cell Mediated Immunity (CMI) Response In A Subset of Participants Expressed As Group Geometric Mean Of The Frequency Of RSVPreF3-Specific Cluster Of Differentiation (CD) 4+ T Cells

    CMI response is expressed as group geometric mean of the frequency of RSVPreF3-specific cluster of differentiation CD4+ T cells expressing at least 2 activation markers including at least one cytokine among CD40L, 4-1BB, IL-2, TNF-alpha, IFN-gamma, IL- 13 and IL-17. The CMI is measured in a subgroup consisting of participants with renal and lung SOT (from RSV\_IC\_1 and RSV\_IC\_2 groups) and healthy participants (from RSV\_HA group).

    Time frame: At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 (Visit 1 + 7-14 days), Visit 3 (Visit 1 + 30-60 days), Visit 4 (Visit 3 + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)

  12. CMI Response In A Subset of Participants Expressed As Group Geometric Mean Of The Frequency Of RSVPreF3-Specific CD8+ T Cells

    CMI response is expressed as group geometric mean of the frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers including at least one cytokine among CD40L, 4-1BB, IL-2, TNF-alpha, IFN-gamma, IL- 13 and IL-17. The CMI is measured in a subgroup consisting of participants with renal and lung SOT (from RSV\_IC\_1 and RSV\_IC\_2 groups) and healthy participants (from RSV\_HA group).

    Time frame: At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 (Visit 1 + 7-14 days), Visit 3 (Visit 1 + 30-60 days), Visit 4 (Visit 3 + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)

  13. Number Of Participants Reporting Any Solicited Administration Site Events

    Assessed solicited administration site events included pain, erythema (redness) and swelling, at the injection site. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: Within 7 days (i.e., the day of vaccination and 6 subsequent days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 +30-60 days] for RSV_IC_2 group)

  14. Number Of Participants Reporting Any Solicited Systemic Events

    Assessed solicited systemic events included fever (pyrexia), myalgia, arthralgia, headache, and fatigue. Fever is defined as body temperature greater or equal to (≥) 38 degrees Celsius (ºC). Any = occurrence of the symptom regardless of intensity grade.

    Time frame: Within 7 days (i.e., the day of vaccination and 6 subsequent days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 +30-60 days] for RSV_IC_2 group)

  15. Number Of Participants Reporting Any Unsolicited Adverse Events (AEs) At Any Dose Administration

    An unsolicited AE is an AE that was not included in the list of solicited events. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.

    Time frame: Within 30 days (i.e., the day of vaccination and 29 subsequent days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 +30-60 days] for RSV_IC_2 group)

  16. Number Of Participants Reporting Any Serious Adverse Events (SAEs), SAEs Related To Study Intervention And Fatal SAEs

    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant. Any SAE = occurrence of the SAE regardless of intensity grade or relation to study intervention. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of intensity grade or relation to study intervention.

    Time frame: From Visit 1 (Day 1) up to Visit 6 (last dose + 350-380 days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)

  17. Number Of Participants Reporting Any Potential Immune-Mediated Disease (pIMDs) And pIMDs Related To Study Intervention

    pIMDs are a subset of AESIs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of intensity grade or relation to study intervention. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination.

    Time frame: From Visit 1 (Day 1) up to Visit 6 (last dose + 350-380 days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)

  18. Number Of Participants With Any AEs Of Special Interest (AESIs) Specific To Renal And Lung Solid Organ Transplant (SOT) Participants

    AESIs include the acute rejection of transplant (specific to renal and lung SOT participants). Analysis was performed only on participants that received transplant in RSV\_IC\_1 and RSV\_IC\_2 groups.

    Time frame: From Visit 1 (Day 1) up to Visit 6 (last dose + 350-380 days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)

07

Results

Posted Jul 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneRSV_IC_1 GroupRSV_IC_2 GroupRSV_HA Group
Started131130125
Completed129125123
Not completed252
Withdrew: Unsolicited non-sae010
Withdrew: Saes/pimds/aesis specific to sot131
Withdrew: Withdrawal by participant: burden of procedure010
Withdrew: Withdrawal by participant: participant relocated101

Outcome measures

PrimaryRSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group

MGI was defined as the geometric mean of the within-participant ratios of serum neutralizing titers against RSV-A post-Dose 2 (Visit 4) over post-Dose 1 (Visit 3).

Time frame:
At Visit 4 (Visit 3 + 30-42 days) compared with Visit 3 (Visit 1 [Day 1] + 30-60 days)
Reported as:
Geometric mean · Ratio
RSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group
RatioRSV_IC_2 Group
RSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group1.34 (1.20 to 1.48)
PrimaryRSV-B Serum Neutralizing Titers Expressed As MGI Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group

MGI was defined as the geometric mean of the within-participant ratios of serum neutralizing titers against RSV-B post-Dose 2 (Visit 4) over post-Dose 1 (Visit 3).

Time frame:
At Visit 4 (Visit 3 + 30-42 days) compared with Visit 3 (Visit 1 [Day 1] + 30-60 days)
Reported as:
Geometric mean · Ratio
RSV-B Serum Neutralizing Titers Expressed As MGI Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group
RatioRSV_IC_2 Group
RSV-B Serum Neutralizing Titers Expressed As MGI Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group1.26 (1.14 to 1.40)
SecondaryRSV-A And RSV-B Serum Neutralizing Titers Expressed As Geometric Mean Titers (GMT) for RSV_IC_1, RSV_IC_2 and RSV_HA Groups

Neutralizing titers were calculated as GMT and expressed in titers (Estimated Dilution 60 \[ED60\]).

Time frame:
At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 in a subset of participants (Visit 1+ 7-14 days), Visit 3 (Visit 1+ 30-60 days), Visit 4 (Visit 3+ 30-42 days), Visit 5 (last dose+ 180-210 days) and Visit 6 (last dose+ 350-380 days)
Reported as:
Geometric mean · Titers (ED60)
RSV-A And RSV-B Serum Neutralizing Titers Expressed As Geometric Mean Titers (GMT) for RSV_IC_1, RSV_IC_2 and RSV_HA Groups
Titers (ED60)RSV_IC_1 GroupRSV_IC_2 GroupRSV_HA Group
RSV-A , Visit 1807.0 (700.9 to 929.2)814.1 (701.3 to 945.1)889.0 (781.9 to 1010.6)
RSV-A , Visit 21775.8 (1201.0 to 2625.6)2031.1 (1283.6 to 3213.9)6716.8 (4907.6 to 9193.0)
RSV-A , Visit 33990.8 (3219.4 to 4947.0)4174.0 (3230.7 to 5392.6)6881.3 (5976.2 to 7923.6)
RSV-A , Visit 44184.7 (3360.1 to 5211.7)5377.9 (4265.4 to 6780.6)5707.0 (4853.6 to 6710.3)
RSV-A , Visit 53220.8 (2637.4 to 3933.3)3954.5 (3205.4 to 4878.6)3958.4 (3372.2 to 4646.6)
RSV-A , Visit 61773.4 (1486.2 to 2116.2)2517.4 (2039.3 to 3107.5)2243.6 (1925.0 to 2614.9)
RSV-B, Visit 1864.2 (727.8 to 1026.2)892.9 (754.1 to 1057.3)1027.3 (889.6 to 1186.3)
RSV-B, Visit 22325.3 (1592.9 to 3394.5)2603.1 (1714.9 to 3951.3)8113.6 (5699.9 to 11549.5)
RSV-B, Visit 35002.9 (3901.7 to 6414.8)4834.7 (3736.6 to 6255.6)9125.2 (7781.9 to 10700.5)
RSV-B, Visit 44461.7 (3519.0 to 5657.0)5820.8 (4658.2 to 7273.5)6281.6 (5377.6 to 7337.7)
RSV-B, Visit 52926.9 (2364.0 to 3623.8)3620.7 (2974.9 to 4406.7)3584.5 (3093.6 to 4153.3)
RSV-B, Visit 62206.7 (1811.3 to 2688.5)2886.5 (2368.0 to 3518.4)2665.1 (2310.9 to 3073.5)
SecondaryRSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_HA And Pooled RSV_IC Groups

Group GMT was assessed for RSV\_HA group over pooled RSV\_IC group (combined RSV\_IC\_1 and RSV\_IC\_2 groups). The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_HA and Pooled RSV\_IC groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Time frame:
At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days) and Visit 3 (Visit 1 + 30-60 days)
Reported as:
Geometric mean · Titers (ED60)
RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_HA And Pooled RSV_IC Groups
Titers (ED60)RSV_HA GroupPooled RSV_IC Group
Visit 26689.9 (4639.3 to 9646.7)1902.8 (1479.6 to 2446.9)
Visit 36714.9 (5549.8 to 8124.7)4111.4 (3594.3 to 4703.1)
Statistical analysis
  • RSV_HA Group vs Pooled RSV_IC Group · ANCOVA · Gmt ratio: 3.52 · 95% CI 2.26 to 5.48The comparison is done using the group ratio of adjusted GMT (RSV\_HA/Pooled RSV\_IC) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
  • RSV_HA Group vs Pooled RSV_IC Group · ANCOVA · Gmt ratio: 1.63 · 95% CI 1.29 to 2.06The comparison is done using the group ratio of adjusted GMT (RSV\_HA/Pooled RSV\_IC) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
SecondaryRSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_IC_2 Groups

Group GMT of RSV\_IC\_2 over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer and the SOT type as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_IC\_2 groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Time frame:
At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
Reported as:
Geometric mean · Titers (ED60)
RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_IC_2 Groups
Titers (ED60)RSV_IC_1 GroupRSV_IC_2 Group
Visit 44041.9 (3254.8 to 5019.3)5098.4 (4088.8 to 6357.3)
Visit 53198.7 (2642.2 to 3872.5)3726.3 (3035.9 to 4573.8)
Visit 61737.0 (1459.2 to 2067.8)2360.0 (1966.4 to 2832.5)
Statistical analysis
  • RSV_IC_1 Group vs RSV_IC_2 Group · ANCOVA · Gmt ratio: 1.26 · 95% CI 0.94 to 1.69The comparison is done using the group ratio of adjusted GMT (RSV\_IC\_2/RSV\_IC\_1) (ANCOVA model applied to the log10- transformed titers). ANCOVA model included the group as fixed effect, and SOT type and baseline log10-transformed titer as covariate.
  • RSV_IC_1 Group vs RSV_IC_2 Group · ANCOVA · Gmt ratio: 1.16 · 95% CI 0.90 to 1.52The comparison is done using the group ratio of adjusted GMT (RSV\_IC\_2/RSV\_IC\_1) (ANCOVA model applied to the log10- transformed titers). ANCOVA model included the group as fixed effect, and SOT type and baseline log10-transformed titer as covariate.
  • RSV_IC_1 Group vs RSV_IC_2 Group · ANCOVA · Gmt ratio: 1.36 · 95% CI 1.07 to 1.72The comparison is done using the group ratio of adjusted GMT (RSV\_IC\_2/RSV\_IC\_1) (ANCOVA model applied to the log10- transformed titers). ANCOVA model included the group as fixed effect, and SOT type and baseline log10-transformed titer as covariate.
SecondaryRSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_HA Groups

Group GMT of RSV\_HA over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Time frame:
At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
Reported as:
Geometric mean · Titers (ED60)
RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_HA Groups
Titers (ED60)RSV_IC_1 GroupRSV_HA Group
Visit 44244.8 (3551.8 to 5073.0)5541.6 (4622.0 to 6644.2)
Visit 53359.9 (2856.5 to 3952.1)3804.2 (3227.3 to 4484.1)
Visit 61830.8 (1578.6 to 2123.4)2192.9 (1889.6 to 2545.0)
Statistical analysis
  • RSV_IC_1 Group vs RSV_HA Group · ANCOVA · Gmt ratio: 1.31 · 95% CI 1.01 to 1.68The comparison is done using the group ratio of adjusted GMT (RSV\_HA/RSV\_IC\_1) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
  • RSV_IC_1 Group vs RSV_HA Group · ANCOVA · Gmt ratio: 1.13 · 95% CI 0.90 to 1.43The comparison is done using the group ratio of adjusted GMT (RSV\_HA/RSV\_IC\_1) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
  • RSV_IC_1 Group vs RSV_HA Group · ANCOVA · Gmt ratio: 1.20 · 95% CI 0.97 to 1.48The comparison is done using the group ratio of adjusted GMT (RSV\_HA/RSV\_IC\_1) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
SecondaryRSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_2 And RSV_HA Groups

Group GMT of RSV\_HA over RSV\_IC\_2 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_2 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Time frame:
At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
Reported as:
Geometric mean · Titers (ED60)
RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_2 And RSV_HA Groups
Titers (ED60)RSV_IC_2 GroupRSV_HA Group
Visit 45505.3 (4627.0 to 6550.3)5615.7 (4719.8 to 6681.6)
Visit 54032.4 (3426.2 to 4746.0)3895.6 (3336.5 to 4548.5)
Visit 62555.4 (2196.4 to 2973.1)2214.8 (1914.0 to 2562.9)
Statistical analysis
  • RSV_IC_2 Group vs RSV_HA Group · ANCOVA · Gmt ratio: 1.02 · 95% CI 0.80 to 1.30The comparison is done using the group ratio of adjusted GMT (RSV\_HA/RSV\_IC\_2) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
  • RSV_IC_2 Group vs RSV_HA Group · ANCOVA · Gmt ratio: 0.97 · 95% CI 0.77 to 1.21The comparison is done using the group ratio of adjusted GMT (RSV\_HA/RSV\_IC\_2) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
  • RSV_IC_2 Group vs RSV_HA Group · ANCOVA · Gmt ratio: 0.87 · 95% CI 0.70 to 1.07The comparison is done using the group ratio of adjusted GMT (RSV\_HA/RSV\_IC\_2) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
SecondaryRSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_HA And Pooled RSV_IC Groups

Group GMT was assessed for RSV\_HA group over pooled RSV\_IC group (combined RSV\_IC\_1 and RSV\_IC\_2 groups). The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_HA and Pooled RSV\_IC groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Time frame:
At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days) and Visit 3 (Visit 1 + 30-60 days)
Reported as:
Geometric mean · Titers (ED60)
RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_HA And Pooled RSV_IC Groups
Titers (ED60)RSV_HA GroupPooled RSV_IC Group
Visit 28238.7 (5972.9 to 11364.1)2442.6 (1958.3 to 3046.7)
Visit 38590.8 (7063.8 to 10448.0)5087.8 (4432.0 to 5840.5)
Statistical analysis
  • RSV_HA Group vs Pooled RSV_IC Group · ANCOVA · Gmt ratio: 3.37 · 95% CI 2.28 to 4.98The comparison is done using the group ratio of adjusted GMT (RSV\_HA/Pooled RSV\_IC) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
  • RSV_HA Group vs Pooled RSV_IC Group · ANCOVA · Gmt ratio: 1.69 · 95% CI 1.33 to 2.15The comparison is done using the group ratio of adjusted GMT (RSV\_HA/Pooled RSV\_IC) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
SecondaryRSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_IC_2 Groups

Group GMT ratio of RSV\_IC\_2 over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer and the SOT type as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_IC\_2 groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Time frame:
At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
Reported as:
Geometric mean · Titers (ED60)
RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_IC_2 Groups
Titers (ED60)RSV_IC_1 GroupRSV_IC_2 Group
Visit 44333.3 (3510.0 to 5349.8)5550.5 (4478.3 to 6879.4)
Visit 52906.8 (2453.2 to 3444.2)3346.4 (2788.7 to 4015.7)
Visit 62158.5 (1851.8 to 2516.0)2689.2 (2290.5 to 3157.2)
Statistical analysis
  • RSV_IC_1 Group vs RSV_IC_2 Group · ANCOVA · Gmt ratio: 1.28 · 95% CI 0.97 to 1.70The comparison is done using the group ratio of adjusted GMT (RSV\_IC\_2/RSV\_IC\_1) (ANCOVA model applied to the log10- transformed titers). ANCOVA model included the group as fixed effect, and SOT type and baseline log10-transformed titer as covariate.
  • RSV_IC_1 Group vs RSV_IC_2 Group · ANCOVA · Gmt ratio: 1.15 · 95% CI 0.91 to 1.45The comparison is done using the group ratio of adjusted GMT (RSV\_IC\_2/RSV\_IC\_1) (ANCOVA model applied to the log10- transformed titers). ANCOVA model included the group as fixed effect, and SOT type and baseline log10-transformed titer as covariate.
  • RSV_IC_1 Group vs RSV_IC_2 Group · ANCOVA · Gmt ratio: 1.25 · 95% CI 1.01 to 1.53The comparison is done using the group ratio of adjusted GMT (RSV\_IC\_2/RSV\_IC\_1) (ANCOVA model applied to the log10- transformed titers). ANCOVA model included the group as fixed effect, and SOT type and baseline log10-transformed titer as covariate.
SecondaryRSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_HA Groups

Group GMT of RSV\_HA over RSV\_IC\_1 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Time frame:
At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
Reported as:
Geometric mean · Titers (ED60)
RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_HA Groups
Titers (ED60)RSV_IC_1 GroupRSV_HA Group
Visit 44632.9 (3890.8 to 5516.6)5973.5 (5000.9 to 7135.4)
Visit 53128.7 (2686.0 to 3644.2)3390.7 (2903.4 to 3960.0)
Visit 62331.2 (2035.7 to 2669.6)2552.1 (2227.3 to 2924.4)
Statistical analysis
  • RSV_IC_1 Group vs RSV_HA Group · ANCOVA · Gmt ratio: 1.29 · 95% CI 1.00 to 1.65The comparison is done using the group ratio of adjusted GMT (RSV\_HA/RSV\_IC\_1) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
  • RSV_IC_1 Group vs RSV_HA Group · ANCOVA · Gmt ratio: 1.08 · 95% CI 0.87 to 1.35The comparison is done using the group ratio of adjusted GMT (RSV\_HA/RSV\_IC\_1) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
  • RSV_IC_1 Group vs RSV_HA Group · ANCOVA · Gmt ratio: 1.09 · 95% CI 0.90 to 1.33The comparison is done using the group ratio of adjusted GMT (RSV\_HA/RSV\_IC\_1) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
SecondaryRSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_2 And RSV_HA Groups

Group GMT of RSV\_HA over RSV\_IC\_2 was assessed at Visit 4, Visit 5 and Visit 6. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_2 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Time frame:
At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
Reported as:
Geometric mean · Titers (ED60)
RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_2 And RSV_HA Groups
Titers (ED60)RSV_IC_2 GroupRSV_HA Group
Visit 46090.6 (5184.6 to 7155.0)6123.0 (5212.1 to 7193.0)
Visit 53770.5 (3294.6 to 4315.1)3509.7 (3087.0 to 3990.1)
Visit 63003.2 (2631.4 to 3427.4)2608.9 (2296.8 to 2963.5)
Statistical analysis
  • RSV_IC_2 Group vs RSV_HA Group · ANCOVA · Gmt ratio: 1.01 · 95% CI 0.80 to 1.26The comparison is done using the group ratio of adjusted GMT (RSV\_HA/RSV\_IC\_2) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
  • RSV_IC_2 Group vs RSV_HA Group · ANCOVA · Gmt ratio: 0.93 · 95% CI 0.77 to 1.12The comparison is done using the group ratio of adjusted GMT (RSV\_HA/RSV\_IC\_2) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
  • RSV_IC_2 Group vs RSV_HA Group · ANCOVA · Gmt ratio: 0.87 · 95% CI 0.72 to 1.04The comparison is done using the group ratio of adjusted GMT (RSV\_HA/RSV\_IC\_2) (ANCOVA model applied to the log10- transformed titers). The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.
SecondaryRSV-A And RSV-B Serum Neutralizing Titers Expressed As MGI

MGI was assessed at Visit 2 (in a subset of participants) over Visit 1 and Visit 3 over Visit 1 in RSV\_HA and pooled RSV\_IC (combined RSV\_IC\_1 and RSV\_IC\_2 groups), and at Visit 4, Visit 5 and Visit 6 over Visit 1 in RSV\_IC\_1, RSV\_IC\_2, RSV\_HA groups.

Time frame:
At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days), Visit 3 (Visit 1 + 30-60 days), Visit 4 (Visit 3 + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days), each compared to Visit 1 (Day 1)
Reported as:
Geometric mean · Ratio
RSV-A And RSV-B Serum Neutralizing Titers Expressed As MGI
RatioRSV_IC_1 GroupRSV_IC_2 GroupRSV_HA GroupPooled RSV_IC Group
RSV-A, Visit 22.38 (1.61 to 3.53)2.36 (1.56 to 3.58)8.48 (6.01 to 11.96)2.37 (1.80 to 3.14)
RSV-A, Visit 35.55 (4.44 to 6.95)5.90 (4.69 to 7.41)8.77 (7.56 to 10.17)5.72 (4.88 to 6.70)
RSV-A, Visit 46.88 (5.49 to 8.61)8.58 (6.92 to 10.62)7.78 (6.66 to 9.09)—
RSV-A, Visit 54.46 (3.65 to 5.44)4.77 (3.93 to 5.79)4.54 (3.91 to 5.27)—
RSV-A, Visit 62.70 (2.26 to 3.22)3.50 (2.96 to 4.14)2.98 (2.56 to 3.47)—
RSV-B, Visit 22.51 (1.78 to 3.55)2.54 (1.75 to 3.67)8.59 (6.59 to 11.20)2.53 (1.98 to 3.23)
RSV-B, Visit 35.72 (4.53 to 7.21)5.34 (4.25 to 6.72)8.95 (7.81 to 10.25)5.53 (4.71 to 6.51)
RSV-B, Visit 45.22 (4.20 to 6.49)6.52 (5.34 to 7.97)6.35 (5.50 to 7.33)—
RSV-B, Visit 53.52 (2.92 to 4.25)3.95 (3.38 to 4.61)3.59 (3.13 to 4.10)—
RSV-B, Visit 62.58 (2.20 to 3.04)3.17 (2.73 to 3.68)2.69 (2.35 to 3.08)—
SecondaryCell Mediated Immunity (CMI) Response In A Subset of Participants Expressed As Group Geometric Mean Of The Frequency Of RSVPreF3-Specific Cluster Of Differentiation (CD) 4+ T Cells

CMI response is expressed as group geometric mean of the frequency of RSVPreF3-specific cluster of differentiation CD4+ T cells expressing at least 2 activation markers including at least one cytokine among CD40L, 4-1BB, IL-2, TNF-alpha, IFN-gamma, IL- 13 and IL-17. The CMI is measured in a subgroup consisting of participants with renal and lung SOT (from RSV\_IC\_1 and RSV\_IC\_2 groups) and healthy participants (from RSV\_HA group).

Time frame:
At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 (Visit 1 + 7-14 days), Visit 3 (Visit 1 + 30-60 days), Visit 4 (Visit 3 + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
Reported as:
Geometric mean · Specific CD4+ Tcells/million CD4+ Tcells
Cell Mediated Immunity (CMI) Response In A Subset of Participants Expressed As Group Geometric Mean Of The Frequency Of RSVPreF3-Specific Cluster Of Differentiation (CD) 4+ T Cells
Specific CD4+ Tcells/million CD4+ TcellsRSV_IC_1 GroupRSV_IC_2 GroupRSV_HA Group
Visit 186.8 ± 1.0110.3 ± 0.9107.8 ± 0.9
Visit 22932.2 ± 0.63704.3 ± 0.52959.8 ± 0.3
Visit 31049.0 ± 0.81626.7 ± 0.31042.4 ± 0.3
Visit 4910.8 ± 0.82709.0 ± 0.3734.4 ± 0.3
Visit 5845.4 ± 0.51452.7 ± 0.4503.7 ± 0.6
Visit 6794.4 ± 0.51131.9 ± 0.5506.4 ± 0.3
SecondaryCMI Response In A Subset of Participants Expressed As Group Geometric Mean Of The Frequency Of RSVPreF3-Specific CD8+ T Cells

CMI response is expressed as group geometric mean of the frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers including at least one cytokine among CD40L, 4-1BB, IL-2, TNF-alpha, IFN-gamma, IL- 13 and IL-17. The CMI is measured in a subgroup consisting of participants with renal and lung SOT (from RSV\_IC\_1 and RSV\_IC\_2 groups) and healthy participants (from RSV\_HA group).

Time frame:
At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 (Visit 1 + 7-14 days), Visit 3 (Visit 1 + 30-60 days), Visit 4 (Visit 3 + 30-42 days), Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
Reported as:
Geometric mean · Specific CD8+ Tcells/million CD8+ Tcells
CMI Response In A Subset of Participants Expressed As Group Geometric Mean Of The Frequency Of RSVPreF3-Specific CD8+ T Cells
Specific CD8+ Tcells/million CD8+ TcellsRSV_IC_1 GroupRSV_IC_2 GroupRSV_HA Group
Visit 133.9 ± 1.08.2 ± 1.127.7 ± 1.0
Visit 216.0 ± 1.28.7 ± 1.013.0 ± 1.2
Visit 321.7 ± 0.822.3 ± 1.121.0 ± 1.1
Visit 412.0 ± 1.116.9 ± 0.913.2 ± 1.1
Visit 512.6 ± 1.014.4 ± 1.18.2 ± 1.1
Visit 614.2 ± 1.020.5 ± 1.110.6 ± 1.1
SecondaryNumber Of Participants Reporting Any Solicited Administration Site Events

Assessed solicited administration site events included pain, erythema (redness) and swelling, at the injection site. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
Within 7 days (i.e., the day of vaccination and 6 subsequent days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 +30-60 days] for RSV_IC_2 group)
Reported as:
Count of participants · Participants
Number Of Participants Reporting Any Solicited Administration Site Events
ParticipantsRSV_IC_1 GroupRSV_IC_2 GroupRSV_HA Group
Pain, Within 7 days from Dosing at Visit 1959295
Pain, Within 7 days from Dosing at Visit 3—82—
Erythema, Within 7 days from Dosing at Visit 181411
Erythema, Within 7 days from Dosing at Visit 3—10—
Swelling, Within 7 days from Dosing at Visit 18113
Swelling, Within 7 days from Dosing at Visit 3—6—
SecondaryNumber Of Participants Reporting Any Solicited Systemic Events

Assessed solicited systemic events included fever (pyrexia), myalgia, arthralgia, headache, and fatigue. Fever is defined as body temperature greater or equal to (≥) 38 degrees Celsius (ºC). Any = occurrence of the symptom regardless of intensity grade.

Time frame:
Within 7 days (i.e., the day of vaccination and 6 subsequent days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 +30-60 days] for RSV_IC_2 group)
Reported as:
Count of participants · Participants
Number Of Participants Reporting Any Solicited Systemic Events
ParticipantsRSV_IC_1 GroupRSV_IC_2 GroupRSV_HA Group
Fever, Within 7 days from Dosing at Visit 1211
Fever, Within 7 days from Dosing at Visit 3—2—
Myalgia, Within 7 days from Dosing at Visit 1373849
Myalgia, Within 7 days from Dosing at Visit 3—38—
Arthralgia, Within 7 days from Dosing at Visit 1191515
Arthralgia, Within 7 days from Dosing at Visit 3—19—
Headache, Within 7 days from Dosing at Visit 1313344
Headache, Within 7 days from Dosing at Visit 3—30—
Fatigue, Within 7 days from Dosing at Visit 1414548
Fatigue, Within 7 days from Dosing at Visit 3—47—
SecondaryNumber Of Participants Reporting Any Unsolicited Adverse Events (AEs) At Any Dose Administration

An unsolicited AE is an AE that was not included in the list of solicited events. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.

Time frame:
Within 30 days (i.e., the day of vaccination and 29 subsequent days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 +30-60 days] for RSV_IC_2 group)
Reported as:
Count of participants · Participants
Number Of Participants Reporting Any Unsolicited Adverse Events (AEs) At Any Dose Administration
ParticipantsRSV_IC_1 GroupRSV_IC_2 GroupRSV_HA Group
Within 7 days from Dosing at Visit 1233327
Within 7 days from Dosing at Visit 3—39—
SecondaryNumber Of Participants Reporting Any Serious Adverse Events (SAEs), SAEs Related To Study Intervention And Fatal SAEs

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant. Any SAE = occurrence of the SAE regardless of intensity grade or relation to study intervention. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of intensity grade or relation to study intervention.

Time frame:
From Visit 1 (Day 1) up to Visit 6 (last dose + 350-380 days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)
Reported as:
Count of participants · Participants
Number Of Participants Reporting Any Serious Adverse Events (SAEs), SAEs Related To Study Intervention And Fatal SAEs
ParticipantsRSV_IC_1 GroupRSV_IC_2 GroupRSV_HA Group
Any SAEs29374
Related SAEs100
Fatal SAEs330
SecondaryNumber Of Participants Reporting Any Potential Immune-Mediated Disease (pIMDs) And pIMDs Related To Study Intervention

pIMDs are a subset of AESIs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of intensity grade or relation to study intervention. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination.

Time frame:
From Visit 1 (Day 1) up to Visit 6 (last dose + 350-380 days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)
Reported as:
Count of participants · Participants
Number Of Participants Reporting Any Potential Immune-Mediated Disease (pIMDs) And pIMDs Related To Study Intervention
ParticipantsRSV_IC_1 GroupRSV_IC_2 GroupRSV_HA Group
Any pIMD211
Related pIMD000
SecondaryNumber Of Participants With Any AEs Of Special Interest (AESIs) Specific To Renal And Lung Solid Organ Transplant (SOT) Participants

AESIs include the acute rejection of transplant (specific to renal and lung SOT participants). Analysis was performed only on participants that received transplant in RSV\_IC\_1 and RSV\_IC\_2 groups.

Time frame:
From Visit 1 (Day 1) up to Visit 6 (last dose + 350-380 days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)
Reported as:
Count of participants · Participants
Number Of Participants With Any AEs Of Special Interest (AESIs) Specific To Renal And Lung Solid Organ Transplant (SOT) Participants
ParticipantsRSV_IC_1 GroupRSV_IC_2 Group
Number Of Participants With Any AEs Of Special Interest (AESIs) Specific To Renal And Lung Solid Organ Transplant (SOT) Participants01

Adverse events

Collected over Solicited AEs: within 7 days post each dose administration, and unsolicited AEs: within 30 days post each dose administration, where doses were administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1(Day 1) + 30-60 days] for RSV_IC_2 group). SAEs, related SAEs, fatal SAEs, pIMDs, related pIMDs and AESIs specific for renal/lung transplant: Visit 1 (Day 1) to Visit 6 (last dose + 350-380 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RSV_IC_1 Group3/131 (2.3%)29/131 (22.1%)106/131 (80.9%)
RSV_IC_2 Group3/130 (2.3%)37/130 (28.5%)120/130 (92.3%)
RSV_HA Group0/125 (0%)4/125 (3.2%)111/125 (88.8%)
Most frequent serious events
Showing 10 of 97
Most frequent serious events
EventRSV_IC_1 GroupRSV_IC_2 GroupRSV_HA Group
PneumoniaInfections and infestations3/1315/1300/125
SepsisInfections and infestations1/1314/1300/125
COVID-19Infections and infestations0/1314/1300/125
Acute kidney injuryRenal and urinary disorders0/1313/1300/125
PyrexiaGeneral disorders0/1313/1300/125
Urinary tract infectionInfections and infestations2/1312/1300/125
UrosepsisInfections and infestations1/1312/1300/125
ColitisGastrointestinal disorders0/1312/1300/125
Urinary retentionRenal and urinary disorders0/1312/1300/125
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/1312/1300/125
Most frequent other events
Showing 10 of 116
Most frequent other events
EventRSV_IC_1 GroupRSV_IC_2 GroupRSV_HA Group
Administration site painGeneral disorders95/131108/13095/125
FatigueGeneral disorders41/13161/13049/125
MyalgiaMusculoskeletal and connective tissue disorders38/13156/13049/125
HeadacheNervous system disorders32/13146/13044/125
ArthralgiaMusculoskeletal and connective tissue disorders19/13127/13015/125
Administration site erythemaGeneral disorders8/13119/13011/125
Administration site swellingGeneral disorders8/13113/1303/125
Administration site pruritusGeneral disorders0/1315/1301/125
DiarrhoeaGastrointestinal disorders1/1315/1300/125
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/1311/1304/125

Baseline characteristics

Exposed set included all participants that received at least one study intervention.

Age, Continuous
Age, Continuous(YEARS)RSV_IC_1 GroupRSV_IC_2 GroupRSV_HA GroupTotal
Mean62.1 ± 9.361.4 ± 8.463.8 ± 8.262.4 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)RSV_IC_1 GroupRSV_IC_2 GroupRSV_HA GroupTotal
Female545066170
Male778059216
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RSV_IC_1 GroupRSV_IC_2 GroupRSV_HA GroupTotal
White897995263
American Indian Or Alaska Native0101
Asian29392492
Black Or African American118423
Not Reported1203
Multiple1012
Unknown0112
08

Study locations

46 sites
  • GSK Investigational Site
    Phoenix, Arizona 85013, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Lexington, Kentucky 40536, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55455, United States
  • GSK Investigational Site
    St Louis, Missouri 63110, United States
  • GSK Investigational Site
    Omaha, Nebraska 68198-2456, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    New York, New York 10065, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • GSK Investigational Site
    Temple, Texas 76502, United States
  • GSK Investigational Site
    Camperdown, New South Wales 2050, Australia
  • GSK Investigational Site
    Birtinya, Queensland 4556, Australia
  • GSK Investigational Site
    Herston, Queensland 4029, Australia
  • GSK Investigational Site
    Adelaide, South Australia 5000, Australia
  • GSK Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • GSK Investigational Site
    London, Ontario N6A 5A5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1J 2G2, Canada
  • GSK Investigational Site
    Giessen, 35392, Germany
  • GSK Investigational Site
    Milan, 20122, Italy
  • GSK Investigational Site
    Milan, 20132, Italy
  • GSK Investigational Site
    Palermo, 90127, Italy
  • GSK Investigational Site
    Pavia, 27100, Italy
  • GSK Investigational Site
    Siena, 53100, Italy
  • GSK Investigational Site
    Aichi, 466-8650, Japan
  • GSK Investigational Site
    Aichi, 470-1192, Japan
  • GSK Investigational Site
    Fukuoka, 814-0180, Japan
  • GSK Investigational Site
    Hyōgo, 662-0918, Japan
  • GSK Investigational Site
    Kumamoto, 861-8520, Japan
  • GSK Investigational Site
    Okayama, 700-8558, Japan
  • GSK Investigational Site
    Tokyo, 160-0017, Japan
  • GSK Investigational Site
    Tokyo, 193-0998, Japan
  • GSK Investigational Site
    Seoul, 03722, South Korea
  • GSK Investigational Site
    Seoul, 110-774, South Korea
  • GSK Investigational Site
    Seoul, 138-736, South Korea
  • GSK Investigational Site
    A Coruña, 15006, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Barcelona, 08907, Spain
  • GSK Investigational Site
    Córdoba, 14004, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28222, Spain
  • GSK Investigational Site
    Santander, 39011, Spain
09

References and documents

Publications

  • Vyse A, Hockey C, Wright H, Ellsbury G. Could more adults than just those aged 75-79 years potentially benefit from vaccination against RSV: insights from UK data. J Pharm Policy Pract. 2025 Nov 4;18(1):2576618. doi: 10.1080/20523211.2025.2576618. eCollection 2025. PubMed 41199924 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jun 2024, 10 months.

Results were first posted in Jul 2025, 1 year after primary completion.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 10 months is close to that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2023
First posted
Jun 27, 2023
StartActual
Jul 28, 2023
Primary completionActual
Jun 25, 2024
CompletionActual
May 16, 2025
Results first posted
Jul 16, 2025
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05921903
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 27, 2023
Start date
Jul 28, 2023
Primary completion
Jun 25, 2024
Completion
May 16, 2025
Results posted
Jul 16, 2025
Last update
Jun 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arexvy

Start the discussion